Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Search
Where to meet us
Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.
Official partner to Cat Care for Life
Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Animal Health Partnering Interests Oral Health May 2024 CORP
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Boehringer unveils first global sustainability publication
Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’
Quick response in fighting Foot-and-Mouth-Disease
Helping to contain an outbreak of the disease on the island of Rodrigues in just six days.
Sharing knowledge from our medical device development
Why do we share some of our work beyond Boehringer for free?
On the road with sanitation workers in India
Exhaust fumes, heat, work and traffic accidents. Overcoming all these odds, the sanitation workers in India fight a daily battle.
Our partners university of georgia
We're partnering with the University of Georgia to address unmet needs and find solutions to some of the biggest challenges in animal health.
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Inauguration of new integrated Asian Veterinary R&D Center in China
Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
Diabetes dog symptoms chronic disease management
Learn about the symptoms of canine diabetes and how to manage the disease.
Award winning employers
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
The Unwearable Collection™ Evolution
Get ready for the next stage of The Unwearable Collection™
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
A Unique Bond: a brotherhood like no other
After being diagnosed with diabetes, Eric’s unique bonds with Peetey and Jake meant they could run miles across the Idaho wilderness.